- Title
- Long-term quality-of-life outcomes following prostate radiotherapy with or without high-dose-rate brachytherapy boost: post-hoc analysis of TROG 03.04 RADAR
- Creator
- Ong, Wee Loon; Nikitas, John; Nickols, Nicholas G.; Chang, Albert; Zaorsky, Nicholas G.; Spratt, Daniel E.; Romero, Tahmineh; Kishan, Amar U.; Joseph, David; Steigler, Allison; Millar, Jeremy; Valle, Luca; Steinberg, Michael L.; Martin, Ting; Reiter, Robert E.; Rettig, Matthew B.
- Relation
- International Journal of Radiation Oncology*Biology*Physics Vol. 119, Issue 3, p. 813-825
- Publisher Link
- http://dx.doi.org/10.1016/j.ijrobp.2023.09.051
- Publisher
- Elsevier
- Resource Type
- journal article
- Date
- 2024
- Description
- Purpose: Adding high-dose-rate brachytherapy (BT) boost to external beam radiation therapy (EBRT) improves biochemical control but may affect patient-reported quality of life (QOL). We sought to determine long-term QOL outcomes for EBRT+BT versus EBRT alone. Methods and Materials: This was a post hoc analysis of the Trans-Tasman Radiation Oncology Group 03.04 Randomized Androgen Deprivation and Radiotherapy (TROG 03.04 RADAR) trial. Only patients who received 74 Gy conventionally fractionated EBRT (n = 260) or 46 Gy conventionally fractionated EBRT plus 19.5 Gy in 3 fractions high-dose-rate BT boost (n = 237) were included in this analysis. The primary endpoint was patient-reported QOL measured using the European Organisation for Research and Treatment of Cancer QOL (EORTC QLQ-C30) and prostate-specific QOL module (EORTC QLQ-PR25) questionnaires. We evaluated temporal changes in QOL scores, rates of symptom resolution, and the proportion of men who had decrements from baseline of >2 x the threshold for minimal clinically important change (2 x MCIC) for each domain. Results: At 5, 17, and 29 months after radiation therapy, the EBRT+BT group had 2.5 times (95% confidence interval [CI], 1.4-4.2; P < .001), 2.9 times (95% CI, 1.7-4.9; P < .001), and 2.6 times (95% CI, 1.4-4.6; P = .002) greater odds of reporting 2 x MCIC in urinary QOL score compared with EBRT. There were no differences beyond 29 months. EBRT+BT led to a slower rate of urinary QOL symptom score resolution up to 17 months after radiation therapy compared with EBRT (P < .001) but not at later intervals. In contrast, at the end of the radiation therapy period and at 53 months after radiation therapy, the EBRT+BT group had 0.65 times (95% CI, 0.44-0.96; P = .03) and 0.51 times (95% CI, 0.32-0.79; P = .003) the odds of reporting 2 x MCIC in bowel QOL symptom scores compared with EBRT. There were no significant differences in the rate of bowel QOL score resolution. There were no significant differences in global health status or sexual activity scores between the 2 groups. Conclusions: There were no persistent differences in patient-reported QOL measures between EBRT alone and EBRT+BT. BT boost does not appear to negatively affect long-term, patient-reported QOL.
- Subject
- brachytherapy (BT); quality of life; prostate; radiation therapy
- Identifier
- http://hdl.handle.net/1959.13/1505747
- Identifier
- uon:55724
- Identifier
- ISSN:0360-3016
- Language
- eng
- Reviewed
- Hits: 8
- Visitors: 8
- Downloads: 0